Hamel Associates’s Moderna MRNA Stock Holding History

Hamel Associates’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-810	Closed	-$312K	–	75
2021 Q3	$312K	Buy	+810	New	+$299K	0.12%	62

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hamel Associates's MRNA Position: Q4 2021 in Review

Hamel Associates sold out of Moderna (MRNA) in Q4 2021, closing a stake of 810 shares — an estimated $312K sold.

Hamel Associates first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $312K in Q3 2021. 1,110 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Hamel Associates reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Hamel Associates sold 810 Moderna shares in Q4 2021, an estimated $312K.
Hamel Associates first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Hamel Associates's Moderna position peaked at $312K in Q3 2021.
1,110 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Hamel Associates's 13F filing for Q4 2021, filed 8 Feb 2022.